Childhood cancer-focused Day One banks $130M for pan-RAF inhibitor

It’s been a busy year for Day One Biopharmaceuticals. Just nine months after debuting with $60 million to tackle childhood cancers, the company is topping up its coffers with a $130 million series B financing. The funds will bankroll development and launch plans for its lead program, a pan-RAF inhibitor it’s developing for children with brain cancer, as well as its search for new drug programs to pick up.